Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials

The recent development of monoclonal antibodies targeted to proprotein convertase subtilisin/kexin type 9 (PCSK9), e.g., PCSK9 inhibitors has revolutionized the landscape of lipid management. Many clinical trials assessing this class have demonstrated remarkable and consistent reductions in low-dens...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Nathan D., Shapiro, Michael D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414420/
https://www.ncbi.nlm.nih.gov/pubmed/30895178
http://dx.doi.org/10.3389/fcvm.2019.00014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414420/
https://www.ncbi.nlm.nih.gov/pubmed/30895178
http://dx.doi.org/10.3389/fcvm.2019.00014

Ejemplares similares